Stockscreener 앱 받기
30.27
5.18%
1.49
시장 영업 전:
31.32
1.05
+3.47%
전일 마감가:
$28.78
열려 있는:
$28.82
하루 거래량:
312.88K
Relative Volume:
0.62
시가총액:
$1.44B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+2.61%
1개월 성능:
+20.26%
6개월 성능:
+171.72%
1년 성능:
+59.23%
1일 변동 폭
$28.03
$30.50
1주일 범위
$27.81
$31.00
52주 변동 폭
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
명칭
Rapport Therapeutics Inc
전화
857-321-8020
주소
99 HIGH STREET, BOSTON
RAPP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
30.27 | 1.37B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-09-16 | 개시 | Truist | Buy |
| 2025-08-06 | 개시 | H.C. Wainwright | Buy |
| 2025-04-08 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-07-02 | 개시 | Jefferies | Buy |
| 2024-07-02 | 개시 | Stifel | Buy |
| 2024-07-02 | 개시 | TD Cowen | Buy |
모두보기
Rapport Therapeutics Inc 주식(RAPP)의 최신 뉴스
Price-Driven Insight from (RAPP) for Rule-Based Strategy - news.stocktradersdaily.com
Wall Street Zen Upgrades Rapport Therapeutics (NASDAQ:RAPP) to Hold - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 5.4%Here's Why - MarketBeat
Rapport Therapeutics Shapes Focused Clinical Neuroscience Programs - Kalkine Media
HC Wainwright Issues Optimistic Forecast for RAPP Earnings - Defense World
FY2027 Earnings Forecast for RAPP Issued By HC Wainwright - MarketBeat
HC Wainwright & Co. Maintains Rapport Therapeutics (RAPP) Buy Recommendation - Nasdaq
H.C. Wainwright raises Rapport Therapeutics stock price target to $40 on strong seizure drug data - Investing.com Canada
Rapport Therapeutics (NASDAQ:RAPP) Receives “Buy” Rating from BTIG Research - Defense World
Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know - sharewise.com
Rapport Therapeutics (NASDAQ:RAPP) Earns Buy Rating from BTIG Research - MarketBeat
BTIG Reiterates Rapport Therapeutics (RAPP) Buy Recommendation - Nasdaq
Citizens reiterates Market Outperform rating on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics (RAPP) Valuation Check After a 60% Year-to-Date Share Price Surge - Yahoo Finance
RAP-219 Phase 2a Seizure Data and Planned Pivotal Trials Might Change The Case For Investing In Rapport Therapeutics (RAPP) - Yahoo Finance
Affinity Asset Advisors LLC Purchases Shares of 199,643 Rapport Therapeutics, Inc. $RAPP - Defense World
Wall Street Zen Downgrades Rapport Therapeutics (NASDAQ:RAPP) to Sell - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to Sell Rating by Wall Street Zen - Defense World
Rapport Therapeutics Announces Positive Phase 2a Post-Hoc Analysis of RAP-219 Demonstrating Early Efficacy in Drug-Resistant Focal Onset Seizures - Quiver Quantitative
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures - The Manila Times
Rapport Therapeutics Announces New Data and Post Hoc - GlobeNewswire
Rapport Therapeutics (RAPP) Valuation After Key Phase 2a Epilepsy Data Presentation Announcement - Sahm
Will Rapport Therapeutics Inc. stock see PE expansionJuly 2025 Momentum & Low Drawdown Momentum Trade Ideas - Newser
Is Rapport Therapeutics Inc. stock trading at a premium valuationWeekly Market Report & Weekly High Conviction Trade Ideas - Newser
(RAPP) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Rapport Therapeutics (RAPP) Stock Analysis Report | Financials & Insights - Benzinga
Rapport Therapeutics COO Cheryl Gault Sells 5,000 Shares - TradingView
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? - sharewise.com
Rapport Therapeutics (RAPP) Is Down 11.3% After Positive Phase 2a Data and $269M Offering – Has the Bull Case Changed? - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Shares Up 6.1%Here's What Happened - MarketBeat
A Look at Rapport Therapeutics’s Valuation as New RAP-219 Phase 2a Data Presentation Approaches - Sahm
How does Rapport Therapeutics Inc (RAPP) change from a tortoise to a hare? - Setenews
Could RAP-219’s Upcoming Data Reveal a Turning Point for Rapport Therapeutics’ Pipeline Strategy (RAPP)? - simplywall.st
Rapport Therapeutics to Present New Phase 2a Data Analysis - GlobeNewswire
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting - Yahoo Finance
What Analyst Ratings Reveal About Sagar Systech Limiteds Future ValueStock Buy Signals & Fast Growing Trading Plans - earlytimes.in
(RAPP) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Can Rapport Therapeutics Inc. stock outperform in 2025 bull marketStop Loss & Long-Term Growth Stock Strategies - newser.com
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at BTIG Research - MarketBeat
Can trapped investors hope for a rebound in Rapport Therapeutics Inc. - newser.com
What institutional flow reveals about Rapport Therapeutics Inc.Weekly Stock Analysis & Daily Entry Point Trade Alerts - newser.com
Will Rapport Therapeutics Inc. stock pay special dividendsJuly 2025 Reactions & Breakout Confirmation Trade Signals - newser.com
This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Analyzing Rapport Therapeutics Inc. with risk reward ratio chartsTreasury Yields & Safe Capital Growth Tips - newser.com
BTIG Research Initiates Coverage on Rapport Therapeutics With Buy Rating, $47 Price Target - MarketScreener
BTIG Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - Nasdaq
What candlestick patterns are forming on Rapport Therapeutics Inc.Gap Up & Verified Entry Point Signals - newser.com
Why Rapport Therapeutics Inc. stock is a value investor pick2025 Technical Overview & Technical Pattern Based Signals - newser.com
Published on: 2025-11-18 22:13:16 - newser.com
Rapport Therapeutics Inc (RAPP) 재무 분석
Rapport Therapeutics Inc (RAPP)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Rapport Therapeutics Inc 주식 (RAPP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gault Cheryl | Chief Operating Officer |
Nov 26 '25 |
Sale |
30.10 |
5,000 |
150,486 |
171,928 |
| Ceesay Abraham | Chief Executive Officer |
Nov 17 '25 |
Sale |
25.19 |
5,833 |
146,931 |
573,746 |
| Ceesay Abraham | Chief Executive Officer |
Nov 17 '25 |
Sale |
25.20 |
5,083 |
128,116 |
35,978 |
| Bredt David | Chief Scientific Officer |
Nov 17 '25 |
Sale |
25.19 |
8,500 |
214,091 |
401,142 |
| Bredt David | Chief Scientific Officer |
Oct 15 '25 |
Sale |
25.79 |
8,500 |
219,196 |
409,642 |
| Ceesay Abraham | Chief Executive Officer |
Oct 15 '25 |
Sale |
25.81 |
5,833 |
150,541 |
579,579 |
| Ceesay Abraham | Chief Executive Officer |
Oct 15 '25 |
Sale |
25.81 |
5,083 |
131,189 |
41,061 |
1.08%
0.91%
자본화:
|
볼륨(24시간):